Latest News and Press Releases

RJ Tesi MD, CEO of INmune Bio, to Present Opening Keynote on Drug Development Strategies to Improve Health Span by Treating the Chronic Diseases of Aging Boca Raton, Florida, July 12, 2023 ...

Analysis of MRI scans in participants from an open label Phase 1b study demonstrates that CDM®, a novel gray matter biomarker, is improved following three months of treatment with XPro1595TM ...

Neutralizing soluble TNF with XPro™ promotes remyelination in cuprizone model after increasing astrocyte and microglia activation responses Boca Raton, Florida, July 10, 2023 (GLOBE...

Presidential Plenary Lecture to be Presented Wednesday, May 31 at the ICST Opening Session BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) announces that Mark...

Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate CancerWebinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE...

BOCA RATON, Fla., May 03, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a...

TNF is involved in the development of Alzheimer’s Disease pathology following traumatic brain injury and is prevented by neutralization of soluble TNF by XPRO™ Boca Raton, Florida, April 19, 2023 ...

Two presentations show targeting high-risk MUC4 expressing HER2+ and Triple Negative Breast Cancer with INB03 reverses resistance mechanisms to immunotherapy "Emerging Targeted...

BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s...